# REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/reach-2-a-randomized-double-blind-placebo-controlled-phase-3-study-of/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Andrew X. Zhu,Yoon‐Koo Kang,Chia‐Jui Yen,Richard S. Finn,Peter R. Galle,Josep M. Llovet,Eric Assénat,Giovanni Brandi,Ho Yeong Lim,Marc Pracht,Kun‐Ming Rau,Philippe Merle,Kenta Motomura,Izumi Ohno,Bruno Daniele,Dongbok Shin,Guido Gerken,Paolo Abada,Yanzhi Hsu,Masatoshi Kudo |
| Citations | 96 |
| DOI | 10.1200/jco.2018.36.15_suppl.4003 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2889699338 |
| Type | conference-abstract |
| Year | 2018 |

## Paper authors

- [Izumi Ohno](https://scholariq.org/researchers/izumi-ohno/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.